Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Vaccines

Free Subscription Articles published in Virology Retrieve available abstracts of 65 articles: HTML format

Single Articles

February 2026
1. LI J, Yang Q, Yang Z, Huyan Y, et al
   Structural and immunogenic characteristics of goose parvovirus virus-like particles.
   Virology. 2026;614:110727.
   PubMed     Abstract available
   
   
   January 2026
2. THOMAS MH, Carlock MA, Ross TM
   Adjuvants enhance protective antibodies against seasonal influenza viruses following a single vaccination of Fluzone.
   Virology. 2026;616:110787.
   PubMed     Abstract available
   
   
   December 2025
3. NGUYEN CT, Nakayama M, Yasui F, Ishigaki H, et al
   Vaccinia virus-based SARS-CoV-2 vaccine prevents lung immunopathology without antibody-dependent enhancement in female rhesus macaques.
   Virology. 2025;616:110778.
   PubMed     Abstract available
   
   
   November 2025
4. LONG J, Liu K, Chen Y, Wang X, et al
   Attenuation of a contemporary Chinese PRRSV-1 strain via serial cell passage and evaluation of its protective efficacy as a modified live virus vaccine candidate.
   Virology. 2025;615:110746.
   PubMed     Abstract available
   
   
   
5. BRICE DC, Andreev K, Miller L, Patton C, et al
   Immunogenicity and efficacy of commercial poultry avian influenza vaccines against HPAI A(H5N1) clade 2.3.4.4b viruses in Mexico.
   Virology. 2025;615:110765.
   PubMed     Abstract available
   
   
   September 2025
6. ELHAZAZ FERNANDEZ A, Abidi S, Mahl K, Scheffler D, et al
   A chiropteran factor of innate immunity can be recruited for rapid rescue and amplification of recombinant modified vaccinia Ankara (MVA).
   Virology. 2025;612:110698.
   PubMed     Abstract available
   
   
   
7. KIM KH, Hwang HS, Lee Y, Jung YJ, et al
   Interferon-gamma receptor signaling is critical for balanced immune activation and protection against influenza after vaccination.
   Virology. 2025;612:110674.
   PubMed     Abstract available
   
   
   August 2025
8. QIAO Y, Tang M, Du M, Zhao C, et al
   H5N1 influenza virus-like particles based on BEVS induce robust functional antibodies and immune responses.
   Virology. 2025;612:110672.
   PubMed     Abstract available
   
   
   
9. BABA S, Koyama T, Komatsu D, Uchino T, et al
   Development of an effective DNA vaccine against ayu atypical cellular gill disease using draft genome information of the causative agent, Plecoglossus altivelis poxvirus.
   Virology. 2025;612:110671.
   PubMed     Abstract available
   
   
   
10. ZENG F, Liu Q, Wang X, Zhong P, et al
    Immunoinformatics design and experimental expression of a multi-epitope vaccine simultaneously targeting AAV2 and HAdV-F41 against acute hepatitis of unknown etiology.
    Virology. 2025;611:110653.
    PubMed     Abstract available
    
    
    
11. ZHANG S, Liu G, Guo A, Chen Y, et al
    Maternal antibody transfer efficiency: The impact of M. bovis-BoHV-1 combined vaccine.
    Virology. 2025;611:110656.
    PubMed     Abstract available
    
    
    June 2025
12. YIN W, Chang C, Zhu Y, Ma F, et al
    Construction of vitamin E-based oil-in-water nano-emulsion adjuvant enhances immunogenicity of inactivated pseudorabies virus vaccine.
    Virology. 2025;610:110616.
    PubMed     Abstract available
    
    
    
13. PASQUALE S, Moscara L, Palmieri C, Martinelli A, et al
    Safety of SARS-CoV-2 XBB.1.5 and seasonal influenza vaccines co-administration: data from a perspective observational active surveillance study. Puglia (Italy), season 2023/2024.
    Virology. 2025;610:110613.
    PubMed     Abstract available
    
    
    
14. FENG S, Huang M, Quan Y, Sun L, et al
    The spike 486 site is a key immune evasion point and a determinant of the immunogenicity of the RBD-dimer mRNA vaccine against SARS-CoV-2 variants.
    Virology. 2025;610:110612.
    PubMed     Abstract available
    
    
    
15. YANG H, Song W, Li Z, Zhu Z, et al
    Genomic characteristics and pathogenicity of three newly isolated NADC34-like PRRSV strains in China and evaluation of one strain for inactivated vaccine candidate.
    Virology. 2025;610:110605.
    PubMed     Abstract available
    
    
    
16. TABYNOV K, Kuanyshbek A, Zharmambet K, Yelchibayeva L, et al
    Evaluation of commercial vaccines for efficacy and transmission control against the emergent H5N8 (clade 2.3.4.4b) avian influenza virus in Kazakhstan.
    Virology. 2025;610:110601.
    PubMed     Abstract available
    
    
    
17. BEAUDOIN-BUSSIERES G, Tauzin A, Dionne K, El Ferri O, et al
    Multiple exposures to SARS-CoV-2 Spike enhance cross-reactive antibody-dependent cellular cytotoxicity against SARS-CoV-1.
    Virology. 2025;607:110512.
    PubMed     Abstract available
    
    
    May 2025
18. SONI S, Kennedy MA, Wang D, Li F, et al
    The role and implication of rotavirus VP8 * in viral infection and vaccine development.
    Virology. 2025;609:110563.
    PubMed     Abstract available
    
    
    
19. CHOI KY, McGregor A
    The guinea pig as a relevant preclinical model in the rat race for a vaccine against congenital cytomegalovirus infection.
    Virology. 2025;610:110560.
    PubMed     Abstract available
    
    
    
20. ISHIGAKI H, Itoh Y
    Translational research on pandemic virus infection using nonhuman primate models.
    Virology. 2025;606:110511.
    PubMed     Abstract available
    
    
    April 2025
21. XU J, Zhang B, Wang B, Ye Z, et al
    The PB subunit vaccine evokes immune response against fox encephalitis.
    Virology. 2025;609:110561.
    PubMed     Abstract available
    
    
    
22. JIANG FY, Xia JY, Jia YJ, Zhu B, et al
    Multi-epitope microsphere vaccine modified immunological efficacy against LMBV in largemouth bass (Micropterus salmoides).
    Virology. 2025;608:110553.
    PubMed     Abstract available
    
    
    
23. SUZUKI Y
    Application of reverse genetics system to Chikungunya virus study.
    Virology. 2025;605:110465.
    PubMed     Abstract available
    
    
    March 2025
24. RAHA JR, Kim KH, Tien Le CT, Bhatnagar N, et al
    A strategy of enhancing the protective efficacy of seasonal influenza vaccines by providing additional immunity to neuraminidase and M2e.
    Virology. 2025;606:110510.
    PubMed     Abstract available
    
    
    
25. BANGA NDZOUBOUKOU JL, Kamara AA, Ullah N, Lei Q, et al
    A meta-analysis on the immunogenicity of prototype, monovalent-adapted and bivalent vaccines against SARS-CoV-2 wildtype, Omicron BA.1 and Omicron BA.4/5 in healthy adults.
    Virology. 2025;606:110509.
    PubMed     Abstract available
    
    
    
26. ZENG L, Bai J, Huang J, Huang S, et al
    Construction and preliminary immunological evaluation of EV-G replicon expressing PEDV-COE-N region.
    Virology. 2025;604:110436.
    PubMed     Abstract available
    
    
    January 2025
27. KORNUTA CA, Bidart JE, Soria I, Quattrocchi V, et al
    Galectin-8 and GEL01 as potential adjuvants to enhance the immune response induced by a DNA vaccine against bovine alphaherpesvirus Type-1.
    Virology. 2025;604:110402.
    PubMed     Abstract available
    
    
    
28. FRAGOSO-SAAVEDRA M, Liu Q
    Towards developing multistrain PEDV vaccines: Integrating basic concepts and SARS-CoV-2 pan-sarbecovirus strategies.
    Virology. 2025;604:110412.
    PubMed     Abstract available
    
    
    
29. WANG N, Yuan C, Wang Z, Yu C, et al
    An effective antiviral strategy based on silence of susceptibility genes through cucumber mosaic virus (CMV) attenuated vaccine vector.
    Virology. 2025;603:110396.
    PubMed     Abstract available
    
    
    
30. ZHAO Y, Li W, Xu L, Tao Z, et al
    Antibody responses in omicron BF.7-infected patients vaccinated with inactivated SARS-CoV-2.
    Virology. 2025;603:110404.
    PubMed     Abstract available
    
    
    
31. SAHA A, Choudhary S, Walia P, Kumar P, et al
    Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction.
    Virology. 2025;604:110394.
    PubMed     Abstract available
    
    
    
32. SULTANA R, Stahelin RV
    Strengths and limitations of SARS-CoV-2 virus-like particle systems.
    Virology. 2025;601:110285.
    PubMed     Abstract available
    
    
    
33. YANG M, Jiao Y, Yan Y, Fu Z, et al
    Recombinant feline herpesvirus-1 (FHV-1) expressing granulocyte colony-stimulating factor (G-CSF) exhibits enhanced protective efficacy in felines.
    Virology. 2025;601:110282.
    PubMed     Abstract available
    
    
    
34. HU W, Tang D, Zeng Z, Wang B, et al
    Research progress on the molecular mechanism of immune escape of porcine reproductive and respiratory syndrome virus.
    Virology. 2025;602:110298.
    PubMed     Abstract available
    
    
    December 2024
35. CALDERON-PEREZ B, Nunez-Munoz LA, Trejo-Ayala LL, Rosales-Garcia VH, et al
    Immunogenicity of a multivalent protein subunit vaccine based on non-glycosylated RBD antigens of SARS-cov-2 and its variants.
    Virology. 2024;603:110380.
    PubMed     Abstract available
    
    
    
36. PENG Y, Luo Y, Pan L, Hou Y, et al
    Immunogenicity analysis based on VP1 and VP2 proteins of bovine enterovirus.
    Virology. 2024;600:110260.
    PubMed     Abstract available
    
    
    November 2024
37. CARCHMAN E, Sanger CB
    Anal cancer prevention: A field in need of scientific Advancement.
    Virology. 2024;602:110323.
    PubMed     Abstract available
    
    
    
38. JIN H, Zhao YR, Huang F, Hong Z, et al
    Vaccinia virus-mediated oncolytic immunotherapy: Emerging strategies for gastrointestinal cancer treatment at dawn.
    Virology. 2024;602:110303.
    PubMed     Abstract available
    
    
    
39. ALI AA, Tabll AA
    Unlocking potential: Virus-like particles as a promising strategy for effective HCV vaccine development.
    Virology. 2024;602:110307.
    PubMed     Abstract available
    
    
    
40. ZHANG J, Pan W, Wang Y, Zhang C, et al
    Corrigendum to "Enhancing vaccine efficacy: Evaluating the superiority of cationic liposome-squalene adjuvant against PCV2 infection" [Virology (2024) 110251].
    Virology. 2024 Nov 7:110271. doi: 10.1016/j.virol.2024.110271.
    PubMed    
    
    
    October 2024
41. ZHANG J, Pan W, Wang Y, Zhang C, et al
    Corrigendum to "Enhancing vaccine efficacy: Evaluating the superiority of cationic liposome-embedded squalene adjuvant against PCV2 infection" [Virol. 600 (2024) 110251].
    Virology. 2024 Oct 21:110263. doi: 10.1016/j.virol.2024.110263.
    PubMed    
    
    
    September 2024
42. RAHARINANTOANINA J, Joffret ML, Bessaud M, Rakoto DAD, et al
    Wide circulation of type 1 vaccine-derived poliovirus strains in clinical specimens from suspected cases of poliomyelitis, their contacts and in wastewater in Madagascar since late 2020.
    Virology. 2024;600:110253.
    PubMed     Abstract available
    
    
    
43. ZHANG J, Pan W, Wang Y, Zhang C, et al
    Enhancing vaccine efficacy: Evaluating the superiority of cationic liposome-embedded squalene adjuvant against PCV2 infection.
    Virology. 2024;600:110251.
    PubMed     Abstract available
    
    
    
44. JANG SO, Lee JH, Chung YJ, Oh HS, et al
    Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response.
    Virology. 2024;600:110243.
    PubMed     Abstract available
    
    
    
45. HERMANN S, Stevens MJA, Sigrist B, Bilic I, et al
    Unveiling the genetic landscape of infectious laryngotracheitis virus in Switzerland: Evidence for vaccine-like and wild-type strains.
    Virology. 2024;600:110217.
    PubMed     Abstract available
    
    
    
46. HUANG WC, Baker WS, Lovell JF, Schein CH, et al
    Displaying alphavirus physicochemical consensus antigens on immunogenic liposomes enhances antibody elicitation in mice.
    Virology. 2024;597:110152.
    PubMed     Abstract available
    
    
    
47. LEI Y, Xu N, Niu C, Chen L, et al
    Specific immunological characteristics and risk factor of XBB variants re-infection in nasopharyngeal carcinoma patients after BA.5 infection.
    Virology. 2024;597:110142.
    PubMed     Abstract available
    
    
    
48. LI S, Tang X, Zhou J, Bian X, et al
    The synergy of recombinant NSP4 and VP4 from porcine rotavirus elicited a strong mucosal response.
    Virology. 2024;597:110130.
    PubMed     Abstract available
    
    
    July 2024
49. MANDVIWALA AS, Huckriede ALW, Arankalle VA, Patil HP, et al
    Mucosal delivery of a prefusogenic-F, glycoprotein, and matrix proteins-based virus-like particle respiratory syncytial virus vaccine induces protective immunity as evidenced by challenge studies in mice.
    Virology. 2024;598:110194.
    PubMed     Abstract available
    
    
    
50. HOUTA MH, Hassan KE, Kilany WH, Shany SAS, et al
    Evaluation of different heterologous-homologous vaccine regimens against challenge with GI-23 lineage infectious bronchitis virus.
    Virology. 2024;598:110193.
    PubMed     Abstract available
    
    
    
51. GILLOT C, Tre-Hardy M, Cupaiolo R, Blairon L, et al
    Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273.
    Virology. 2024;595:110082.
    PubMed     Abstract available
    
    
    June 2024
52. ZHU H, Li X, Li X, Chen H, et al
    Protection against the H1N1 influenza virus using self-assembled nanoparticles formed by lumazine synthase and bearing the M2e peptide.
    Virology. 2024;597:110162.
    PubMed     Abstract available
    
    
    
53. ZHANG B, Li S, Zhou J, Wang W, et al
    A novel virus-like particles vaccine induces broad immune protective against deltacoronavirus in piglets.
    Virology. 2024;597:110150.
    PubMed     Abstract available
    
    
    
54. KIM J, Villar Z, Jobe O, Rerks-Ngarm S, et al
    Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1.
    Virology. 2024;597:110158.
    PubMed     Abstract available
    
    
    
55. ABDEL-MONEIM AS, Murovska M, Soderlund-Venermo M, Vakharia VN, et al
    WSV2023 - The second meeting of the world society for virology: One health - One world - One virology.
    Virology. 2024;594:110049.
    PubMed     Abstract available
    
    
    
56. HE X, Jiang N, Li Y
    Saccharomyces cerevisiae cells that display norovirus P induce both systemic and mucosal neutralizing antibodies.
    Virology. 2024;594:110034.
    PubMed     Abstract available
    
    
    
57. GE P, Ross TM
    COBRA HA and NA vaccination elicits long-live protective immune responses against pre-pandemic H2, H5, and H7 influenza virus subtypes.
    Virology. 2024;597:110119.
    PubMed     Abstract available
    
    
    May 2024
58. TIAN Y, Deng Z, Chuai Z, Li C, et al
    A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge.
    Virology. 2024;596:110125.
    PubMed     Abstract available
    
    
    
59. BROGAARD L, Heegaard PMH, Larsen LE, Skovgaard K, et al
    Pulmonary MicroRNA expression after heterologous challenge with swine influenza A virus (H1N2) in immunized and non-immunized pigs.
    Virology. 2024;596:110117.
    PubMed     Abstract available
    
    
    
60. YANG D, Wang X, Yang X, Qi S, et al
    Construction and immune effect evaluation of the S protein heptad repeat-based nanoparticle vaccine against porcine epidemic diarrhea virus.
    Virology. 2024;596:110113.
    PubMed     Abstract available
    
    
    
61. SHAO J, Liu W, Gao S, Chang H, et al
    A recombinant multi-epitope trivalent vaccine for foot-and-mouth disease virus serotype O in pigs.
    Virology. 2024;596:110103.
    PubMed     Abstract available
    
    
    April 2024
62. MA X, Wang Q, Xu X, Zhang W, et al
    miR-214-PTEN pathway is a potential mechanism for stress-induced immunosuppression affecting chicken immune response to avian influenza virus vaccine.
    Virology. 2024;595:110094.
    PubMed     Abstract available
    
    
    
63. KIM KH, Bhatnagar N, Subbiah J, Liu R, et al
    Cross-protection against influenza viruses by chimeric M2e-H3 stalk protein or multi-subtype neuraminidase plus M2e virus-like particle vaccine in ferrets.
    Virology. 2024;595:110097.
    PubMed     Abstract available
    
    
    March 2024
64. AMOSOVA IV, Timoshicheva TA, Kadyrova RA, Zabrodskaya YA, et al
    The investigation of the dynamics of changes in neutralizing antibody titers against type 5 adenovirus in the context of vaccination against a new coronavirus infection.
    Virology. 2024;594:110051.
    PubMed     Abstract available
    
    
    
65. ZHENG X, Yang R, Zhao Y, Zhang Y, et al
    Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity.
    Virology. 2024;594:110050.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.